Cytek Biosciences (CTKB) shares surged 6.42% driven by strong preliminary revenue guidance and key market momentum.

Cytek Biosciences (CTKB) shares surged 6.422% in pre-market trading on Jan. 13, 2026, driven by strong preliminary revenue guidance and positive momentum in key markets. The biotech firm reported expected full-year 2025 revenue of $201 million, with Q4 sales reaching $62 million—a 8% year-over-year and 19% sequential increase.

Management highlighted robust performance in Services, Reagents, and Asia Pacific instrument sales, alongside a recovery in EMEA instrument growth. The company attributed the fourth-quarter acceleration to sustained demand across its product suite and operational execution. Cytek will disclose audited results and 2026 guidance in late February, with CEO Wenbin Jiang emphasizing confidence in long-term growth potential within the flow cytometry sector.

The stock’s pre-market rally aligns with its scheduled presentation at the J.P. Morgan Healthcare Conference on Jan. 14. Investors are closely watching for clarity on market expansion strategies and product adoption trends, particularly in clinical diagnostics and high-content screening applications.

Given the company's recent performance and market positioning, analysts are projecting increased interest in Cytek's pipeline developments and potential partnerships. The stock's recent volatility may reflect broader market sentiment toward high-growth biotech firms. Investors are also monitoring global regulatory environments and competitive dynamics in the flow cytometry market, which could influence near-term performance.